Literature DB >> 9202793

Vitamin D metabolites (25-hydroxyvitamin D, 24,25-dihydroxyvitamin D and 1,25-dihydroxyvitamin D) and osteocalcin in beta-thalassaemia.

A Moulas1, A Challa, N Chaliasos, P D Lapatsanis.   

Abstract

Serum levels of the vitamin D metabolites 25-hydroxyvitamin D, 24,25-dihydroxyvitamin D, and 1,25-dihydroxyvitamin D, and of osteocalcin, C-terminal parathyroid hormone and other biochemical indices related to bone metabolism, were determined in two groups of patients with beta-thalassaemia aged 5-10 years (summer 7.8 +/- 0.4 years, mean +/- SEM, and winter 7.7 +/- 0.4 years, group A, n = 15) and 11-23 years (16.6 +/- 0.9 and 15.7 +/- 0.9 years in summer and winter, respectively, group B, n = 22). Emphasis was given to populations of school and adolescent ages and to the seasons of summer and winter when vitamin D status demonstrates the widest extremes. The mean serum levels of 25-hydroxyvitamin D in patients aged 5-10 years did not differ from those of controls during both seasons studied. In contrast, in the age group 11-23 years these levels were found to be lower in patients than in controls both in winter (10.6 +/- 0.9 ng/ml vs 15.0 +/- 2.0 ng/ml, p < 0.05) and summer (20.2 +/- 2.1 ng/ml vs 27.1 +/- 2.0 ng/ml, p < 0.05). The serum concentrations of 24,25-dihydroxyvitamin D were lower in the thalassaemic patients than in controls in both age groups and both seasons. In the patients under 10 years of age the mean values of this metabolite in winter were 1.06 +/- 0.17 ng/ml vs 1.68 +/- 0.20 ng/ml in the respective controls (p < 0.05), and in summer 1.44 +/- 0.11 ng/ml vs 2.35 +/- 0.36 ng/ml in controls (p < 0.05). In the group of patients aged 11-23 years, the mean levels of 24,25-dihydroxyvitamin D were in winter 0.65 +/- 0.12 ng/ml vs 1.12 +/- 0.19 ng/ml (p < 0.05) in controls and in summer 1.34 +/- 0.12 ng/ml vs 1.84 +/- 0.20 ng/ml (p < 0.05). The 1,25-dihydroxyvitamin D concentrations in both thalassaemic patient groups were significantly no different from those in the respective control groups. Serum osteocalcin, C-terminal parathyroid hormone, calcium, inorganic phosphate and alkaline phosphatase levels in the patients studied were not significantly different from those in controls, except for calcium and phosphate in the older group. In the older group of thalassaemic patients, serum calcium was lower than in the controls (2.26 +/- 0.03 vs 2.37 +/- 0.03 mmol/l, p < 0.05) in summer and serum phosphate higher than in the controls in winter (1.47 +/- 0.05 mmol/l vs 1.27 +/- 0.06 mmol/l, p < 0.05).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9202793     DOI: 10.1111/j.1651-2227.1997.tb08940.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  9 in total

1.  A 2-year prospective densitometric study on the influence of Fok-I gene polymorphism in young patients with thalassaemia major.

Authors:  M Dimitriadou; A Christoforidis; L Fidani; M Economou; E Vlachaki; M Athanassiou-Metaxa; G Katzos
Journal:  Osteoporos Int       Date:  2015-08-15       Impact factor: 4.507

2.  Factors associated with 1,25-dihydroxyvitamin D3 concentrations in liver transplant recipients: a prospective observational longitudinal study.

Authors:  Agnieszka Prytuła; Johan Vande Walle; Hans Van Vlierberghe; Jean-Marc Kaufman; Tom Fiers; Jo Dehoorne; Ann Raes
Journal:  Endocrine       Date:  2015-10-03       Impact factor: 3.633

3.  Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes.

Authors:  S Allegra; J Cusato; S De Francia; A Arduino; F Longo; E Pirro; D Massano; A De Nicolò; A Piga; A D'Avolio
Journal:  Pharmacogenomics J       Date:  2017-11-21       Impact factor: 3.550

4.  Endocrine and metabolic disorders in β-thalassemiamajor patients.

Authors:  Fatemeh Saffari; Abolfazl Mahyar; Shabnam Jalilolgadr
Journal:  Caspian J Intern Med       Date:  2012

5.  Osteoporosis syndrome in thalassaemia major: an overview.

Authors:  Meropi Toumba; Nicos Skordis
Journal:  J Osteoporos       Date:  2010-05-26

6.  Vitamin D Receptor (VDR) Gene Polymorphisms (FokI, BsmI) and their Relation to Vitamin D Status in Pediatrics βeta Thalassemia Major.

Authors:  Shereen Mohamed Elhoseiny; Dalia Saber Morgan; Asmaa Mohamed Rabie; Samer Tharwat Bishay
Journal:  Indian J Hematol Blood Transfus       Date:  2015-05-19       Impact factor: 0.900

7.  Vitamin D deficiency, cardiac iron and cardiac function in thalassaemia major.

Authors:  John C Wood; Susan Claster; Susan Carson; J D Menteer; Thomas Hofstra; Rachna Khanna; Thomas Coates
Journal:  Br J Haematol       Date:  2008-03-26       Impact factor: 6.998

Review 8.  A contemporary therapeutic approach to bone disease in beta-thalassemia - a review.

Authors:  Dimitrios Stefanopoulos; Nikolaos A Papaioannou; Athanassios G Papavassiliou; George Mastorakos; Andromachi Vryonidou; Aikaterini Michou; Ismene A Dontas; George Lyritis; Eva Kassi; Symeon Tournis
Journal:  J Frailty Sarcopenia Falls       Date:  2018-03-01

9.  Evaluation of the vitamin D and biomedical statuses of young children with β-thalassemia major at a single center in southern China.

Authors:  Uet Yu; Li Chen; Xiaodong Wang; Xiaoling Zhang; Yue Li; Feiqiu Wen; Sixi Liu
Journal:  BMC Pediatr       Date:  2019-10-23       Impact factor: 2.125

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.